Pfizer Inc.
PFEHealthcare Drug Manufacturers General
Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.
- Revenue
- −0.43%
- EPS
- −9.68%
- Free cash flow
- +20.0%
- Total debt
- +1.55%
Quarter to September 2026, against a year earlier
Follow PFE
Alert me
Pfizer Inc. (PFE) Free cash flow
Pfizer Inc.'s free cash flow for fiscal 2025 was $9.1B, down 7.73% from $9.8B in fiscal 2024. Over the twelve months to Sep 30, 2026 it was $11.8B. Over the past ten years it has ranged from $4.8B (fiscal 2023) to $29.9B (fiscal 2021); the current reading is higher than 18% of that period. Pfizer Inc. ranks 8th of 21 Drug Manufacturers General companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $9.1B | (7.73%) |
| FY2024 | $9.8B | 105.20% |
| FY2023 | $4.8B | (81.59%) |
| FY2022 | $26.0B | (12.85%) |
| FY2021 | $29.9B | 156.65% |
| FY2020 | $11.6B | 14.95% |
| FY2019 | $10.1B | (26.05%) |
| FY2018 | $13.7B | (6.13%) |
| FY2017 | $14.6B | 2.76% |
| FY2016 | $14.2B | 7.59% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $4.8B | 1,490.07% |
| Jun 2026 | $302.0M | (86.14%) |
| Mar 2026 | $2.2B | (51.61%) |
| Dec 2025 | $4.5B | 12.55% |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| SNY Sanofi compare | $23.8B |
| NVS Novartis AG compare | $14.1B |
| GILD Gilead Sciences, Inc. compare | $13.8B |
| PFE Pfizer Inc. | $11.8B |
| AMGN Amgen Inc. compare | $9.6B |
| BMY Bristol Myers Squibb Company compare | $9.3B |
| GSK GSK PLC Sponsored ADR compare | $8.8B |
| NVO Novo Nordisk A/S compare | $6.9B |
| AZN AstraZeneca PLC compare | $6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on PFE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement